Immuno Oncology Drugs Market: By Type (Monoclonal Antibodies, Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Others) By Application (Breast Cancer, Blood cancer, Liver Cancer, Brain cancer, Colorectal Cancer, Others) By End Users (Hospitals, Ambulatory Centers, Clinics, Academic Institutes), By Geography


Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Immuno Oncology Drugs Market size valued at 56.28 billion in 2021 and expected to reach USD 109.67 billion by 2028, at a CAGR of 10% during the forecast period 2022-2028. Immuno-oncology includes utilization of patients’ safe framework to battle against the disease. Immuno-oncology utilizes novel immunotherapies that lift the invulnerable arrangement of patients. These treatments focus on the insusceptible arrangement of the body rather than the tumors and empower the invulnerable framework to perceive and target malignancy cells. Immuno-oncology does not influence the working of solid cells instead of regular treatments, for example, chemotherapy and radiation treatment. Long haul reaction can be created with the assistance of these treatments as they give dependable memory to the resistant framework. Resistant framework adjusts to the malignancy after some time and gives long-haul reaction to the growth. Currently immuno oncology drugs market is witnessing a significant growth. The targeted and combination therapy drugs are leading in the market. Several market player collaborating to develop antibody drugs to treat various type of cancers. Producers are concentrating on redesigning the accessible resistant oncology tranquilizes and in addition growing new safe oncology drugs for tumor treatment. For example, AstraZeneca’s Durvalumab (Imfinzi) was affirmed in 2017, as invulnerable checkpoint inhibitor, which squares cooperation of PD-L1 with PD-1 and CD80. In December 2017, Bristol-Myers Squibb got endorsement for Nivolumab (Opdivo) in adjuvant treatment of melanoma. In August 2017, Novartis got endorsement for CAR-T treatment named Kymriah for youngsters and youthful grown-up with B-cell lymphoblastic lymphoma. Gilead Life Science finished the securing of Kite pharma Ltd. in October 2017, and Gilead’s CAR-T treatment Yescarta got the U.S. Nourishment and Drug Administration (FDA) endorsement in October 2017 to treat non-Hodgkin lymphoma. Celgene Corporation, in January 2018, reported obtaining of Juno Therapeutics, Inc. Through this obtaining, Celgene Corporation will access novel CAR-T treatment, which is in pipeline of Juno Therapeutics. Moreover, Amgen, Inc. gotten FDA endorsement, for Imlygic in 2017, which is an oncolytic infection to treat melanoma. In March 2017, Avelumab (Bavencio), mutually created by EMD Serono, and Pfizer, Inc. gotten FDA endorsement for the treatment of metastatic merkel cell carcinoma. . In January 2017, AbCellera Biologics, Inc. collaborated with Pfizer Inc for new therapeutic antibody discovery. AbCellera will use its monoclonal antibody (mAb) screening techniques in the discovery of function modulating antibodies against undisclosed membrane protein targets.

Immuno Oncology Drugs Market Summary

Study Period


Base Year




Largest Market


Fastest Growing Market

Immuno Oncology Drugs Market

The market growth of immuno oncology drugs is driven by increased prevalence of cancer worldwide. According to WHO, cancer is one of the leading cause of deaths worldwide. In 2012, there were around 14 Mn new cases of cancer, 8.2 Mn people died because of cancer and numbers of new cancer cases are projected to rise 70% in coming decades. In addition, immuno oncology drugs are proved to be having less adverse effects when compared to conventional non-targeted therapies. Increasing investment in the development of immuno oncology drugs, are fueling the sales revenue of immuno oncology drugs market. However, the high cost of development, stringent regulatory guidelines, long period of clinical trials, are some of the factors hinder growth of immuno oncology drugs market.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018-2022), and forecast (2023-2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Immuno Oncology Drugs Market Segmentation

By Type
  • Monoclonal Antibodies
  • Immune Checkpoint Inhibitors
  • Immune System Modulators
  • Cancer Vaccines
  • Others
By Application
  • Breast Cancer
  • Blood cancer
  • Liver Cancer
  • Brain cancer
  • Colorectal Cancer
  • Others

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

  • Merck & Co. Inc. (U.S.)
  • Hoffmann-La Roche AG (Switzerland)
  • Spectrum Pharmaceuticals U.S.)
  • Eli Lilly and Company (U.S.)
  • Amgen Inc. (U.S.)
  • Bristol-Meyer Squibb (U.S.)
  • Sanofi S.A. (France)
  • AstraZeneca plc (U.S.)
  • 3M Company (US)